[go: up one dir, main page]

US20130158106A1 - Tocopherol derivatives and methods of use - Google Patents

Tocopherol derivatives and methods of use Download PDF

Info

Publication number
US20130158106A1
US20130158106A1 US13/701,630 US201113701630A US2013158106A1 US 20130158106 A1 US20130158106 A1 US 20130158106A1 US 201113701630 A US201113701630 A US 201113701630A US 2013158106 A1 US2013158106 A1 US 2013158106A1
Authority
US
United States
Prior art keywords
compound
carbon
carbons
hydrocarbon tail
unsaturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/701,630
Other languages
English (en)
Inventor
Philip J. Breen
K. Sree Kumar
Cesar Compadre
Martin Hauer-Jensen
Kottayil Varughese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Veterans Affairs
BioVentures LLC
Original Assignee
US Department of Veterans Affairs
University of Arkansas at Little Rock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Veterans Affairs, University of Arkansas at Little Rock filed Critical US Department of Veterans Affairs
Priority to US13/701,630 priority Critical patent/US20130158106A1/en
Assigned to UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS reassignment UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAUER-JENSEN, MARTIN
Assigned to THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS reassignment THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KUMAR, K. SREE, VARUGHESE, KOTTAYIL, HAUER-JENSEN, MARTIN, BREEN, PHILIP J., COMPADRE, CESAR
Assigned to UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS reassignment UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAUER-JENSEN, MARTIN
Assigned to THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS reassignment THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KUMAR, K. SREE, VARUGHESE, KOTTAYIL, HAUER-JENSEN, MARTIN, BREEN, PHILIP J., COMPADRE, CESAR
Publication of US20130158106A1 publication Critical patent/US20130158106A1/en
Assigned to BIOVENTURES, LLC reassignment BIOVENTURES, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4

Definitions

  • Vitamin E is composed of eight naturally occurring tocols. Four are tocopherols, which possess a saturated hydrocarbon tail, and four are tocotrienols, which possess three trans double bonds in the hydrocarbon tail.
  • the tocols are known to have beneficial health effects when provided as a dietary supplement. Efficient transport out of the liver is necessary for the tocols to deliver the beneficial health effects.
  • the tocols are transported out of the liver and into the blood stream by a protein called ⁇ TTP (tocopherol transfer protein).
  • ⁇ TTP tocopherol transfer protein
  • the tocotrienols have recently been shown to have some beneficial health effects not seen with the tocopherols.
  • tocol derivatives with modifications to the hydrocarbon tail to allow more efficient binding and uptake of tocols with unsaturated hydrocarbon tails by the ⁇ TTP receptor.
  • the derivatives are called tocoflexols to indicate the increased flexibility of the hydrocarbon tail as compared to tocotrienols and differentiate this class of compounds from the tocopherols and tocotrienols.
  • Tocopherol and tocotrienol derivatives with one to three double bonds in the hydrocarbon tail are described herein.
  • tocol derivative compounds with a chroman group and a hydrocarbon tail having three isoprene units are described herein.
  • the hydrocarbon tail is distinct from that of tocopherol and tocotrienol in that at least one isoprene unit is unsaturated, suitably between carbon 2 and 3 of the isoprene unit and the second isoprene unit in the hydrocarbon tail does not include a trans carbon carbon double bond.
  • R 1 , R 3 , R 4 and R 5 are each independently —H, halogen, —OH, —OCH 3 , or a branched or unbranched, substituted or unsubstituted, saturated or unsaturated C 1 -C 20 alkyl;
  • R 2 is an ester, —OH, —NHR 6 , —CO 2 H, C(R 6 ) 2 CO 2 H or a branched or unbranched, substituted or unsubstituted, saturated or unsaturated C 1 -C 6 alkyl;
  • R 6 is —H, halogen, —OH, or a branched or unbranched, substituted or unsubstituted, saturated or unsaturated C 1 -C 20 alkyl;
  • Y is O, S or NH; and
  • Z is a hydrocarbon side chain having 1 to 3 carbon-carbon double bonds represented by formula (II):
  • the numerals represent the numbering of the carbons in the chain, wherein the dotted lines between carbons 1′, 2′, 3′, 4′ and 16′, and between 15′, 8′, 9′, 10′, 11′, 12′, 13′, and 14′ represent a position for an optional carbon-carbon bond and the dotted line between carbons 7′ and 8′ represent a single bond, a cis carbon-carbon double bond or a cyclopropyl group including carbon 7′ and 8′ and a third carbon that is not shown in the formula.
  • the compounds have a chroman head group of any of the tocol derivatives and a partially unsaturated hydrocarbon tail with a carbon-carbon double bond between carbons 11′ and 12′ or alternatively between any of the carbons in the third isoprene unit.
  • the compounds have a hydrocarbon tail with two carbon-carbon double bonds.
  • the carbon-carbon double bonds are between carbons 15′, 8′, 9′, 10′, 11′, 12′, 13′, and 14′ and at least one of carbons 1′-2′, 2′-3′,3′-4′, ′-8′ and 4′-16′.
  • the compounds have a hydrocarbon tail with three carbon-carbon double bonds.
  • the carbon-carbon double bonds are between at least one of carbons 15′, 8′, 9′, 10′, 11′, 12′, 13′, and 14′ and between carbons 7′ and 8′ and one of carbons 2′-3′, 3′-4′, and 4′-16′.
  • the hydrocarbon tail has a double bond between at least one of carbons 15′, 8′, 9′, 10′, 11′, 12′, 13′, and 14′ and between one of carbons 1′-2′, 2′-3′,3′-4′, and 4′-16′ and contains a cyclopropyl group including carbons 7′ and 8′ and a carbon 17′ not shown in formula II.
  • methods of treating a subject with a condition include administering an effective amount of at least one of the described compounds to the subject to ameliorate the condition.
  • the subject may be in need of treatment with an antioxidant, an anti-inflammatory agent, an immunoregulatory agent, an anti-thromobotic agent, an anti-atherogenic agent, a hypocholesterolemic agent or an HMG-CoA reductase inhibitor.
  • the subject may have a condition selected from radiation exposure, cancer, cardiovascular disease including but not limited to coronary artery disease, decreasing lipoprotein levels, decreasing cholesterol levels, decreasing triglycerides, age-related macular degeneration, cataracts, glaucoma, chronic pain, chronic fatigue syndrome, fever, edema, diabetes mellitus, signs of aging, rheumatoid diseases, septic shock, and Alzheimer's disease.
  • cardiovascular disease including but not limited to coronary artery disease, decreasing lipoprotein levels, decreasing cholesterol levels, decreasing triglycerides, age-related macular degeneration, cataracts, glaucoma, chronic pain, chronic fatigue syndrome, fever, edema, diabetes mellitus, signs of aging, rheumatoid diseases, septic shock, and Alzheimer's disease.
  • FIG. 1 is a schematic of RRR- ⁇ -tocopherol as it would appear when bound to the ⁇ -TTP receptor.
  • FIG. 2 is a schematic of the in silico analysis of the Torsion angles A and B for tocopherol, tocotrienol and the RS and RR configuration of tocoflexol compounds of the invention.
  • the circle represents a key contact between the TTP receptor and the tocol.
  • FIG. 3 is a synthetic scheme for producing a compound of the invention.
  • FIG. 4 is a graph showing the results of a gas chromatography-mass spectrometry experiment demonstrating the ability to detect and differentiate tocol compounds in plasma.
  • tocol derivatives with modifications to the hydrocarbon tail to allow more efficient binding and uptake by the ⁇ TTP receptor and methods of using these compounds.
  • the derivatives are called tocoflexols to indicate the increased flexibility of the hydrocarbon tail relative to the tocotrienols and differentiate this class of compounds from the tocopherols and tocotrienols.
  • Tocopherol and tocotrienol derivatives with one to three double bonds in the hydrocarbon tail are described herein.
  • Tocol derivative compounds with a chroman group and a hydrocarbon tail having three isoprene units are described herein.
  • the chroman group has the basic structure shown in formula I. Many alterations to the chroman head group of the tocols have been described elsewhere and are known to those of skill in the art.
  • the chroman head group of any tocol may be used to generate the compounds descried herein.
  • the hydrocarbon tail is distinct from that of tocopherol in that at least one isoprene unit is unsaturated. Suitably the double bond is between carbon 2 and 3 of the isoprene unit as shown below.
  • the hydrocarbon tail is also distinct from that of the tocotrienols because the second (middle) isoprene unit in the hydrocarbon tail does not include a trans carbon-carbon double bond.
  • the isoprene units has a double bond.
  • the double bond is between carbons 2 and 3 of the isoprene unit as shown by the dotted line in the formula above.
  • the third isoprene unit (the farthest from the chroman head group) has a carbon-carbon double bond between carbon 2 and 3.
  • the hydrocarbon tail has a cis carbon-carbon double bond between carbons 2 and 3 of the second or middle isoprene unit.
  • the compound has a carbon-carbon double bond between carbon 2 and 3 of the third isoprene unit and a cis carbon-carbon double bond between carbons 2 and 3 of the second or middle isoprene unit.
  • the compound may have a cyclopropyl group involving carbons 2 and 3 of the second or middle isoprene unit and an additional carbon that is not part of the basic isoprene unit.
  • This compound may also have a carbon-carbon double bond between carbons 2 and 3 of the third isoprene unit.
  • the second isoprene unit of the hydrocarbon tail may be saturated and the first or first and third isoprene units may be unsaturated.
  • the hydrocarbon tail of tocols must be flexible and able to fold and bend. Tocotrienols, because of the unsaturated hydrocarbon tail, do not bind as efficiently to ⁇ TTP and have lower bioavailability than tocopherols.
  • the hydrocarbon tail of the tocoflexols of the present invention may be folded such that the Torsion angle between carbon 4 of the first isoprene unit and carbons 1, 2, and 3 of the second isoprene unit is about 61.0° and the Torsion angle between carbons 1, 2, 3, and 4 of the second isoprene unit is about 58.4°.
  • the hydrocarbon tail is flexible and can adopt conformations with Torsion angles between 30° and 90°, suitably between 45° and 75°, suitably between 50° and 70°, suitably between 53° and 65° at these positions.
  • Tocopherol and tocotrienol derivatives having one to three unsaturated carbon-carbon bonds on the hydrocarbon tail are provided herein.
  • the compounds provided herein may have the following structural formula:
  • R 1 , R 3 , R 4 and R 5 are each independently —H, halogen, —OH, —OCH 3 , or a branched or unbranched, substituted or unsubstituted, saturated or unsaturated C 1 -C 20 alkyl;
  • R 2 is an ester, —OH, —NHR 6 , —CO 2 H, —C(R 6 ) 2 CO 2 H or a branched or unbranched, substituted or unsubstituted, saturated or unsaturated C 1 -C 6 alkyl or hydroxyalkyl;
  • R 6 is —H, halogen, —OH, or a branched or unbranched, substituted or unsubstituted, saturated or unsaturated C 1 -C 20 alkyl;
  • Y is O, S or NH; and
  • Z is a hydrocarbon side chain having 1 to 3 carbon-carbon double bonds represented by formula (II).
  • the numerals represent the numbering of the carbons in the chain.
  • the dotted lines between carbons 1′, 2′, 3′, 4′ and 16′, and between 15′, 8′, 9′, 10′, 11′, 12′, 13′, and 14′ represent a position for an optional carbon-carbon double bond and the dotted line between carbon 7′ and 8′ represent a single bond, an optional cis carbon-carbon double bond or a cyclopropyl group including both carbon 7′ and 8′ and an additional carbon 17′ not shown in this formula.
  • the compound may have the Torsion angles described above such that the Torsion A angle between carbons 5′, 6′, 7′, and 8 ′ of the hydrocarbon tail of formula II is about 61.0° and the Torsion B angle between carbons 6′, 7′, 8′, and 9′ of the hydrocarbon tail of formula II is about 58.4°.
  • the hydrocarbon tail is flexible and can adopt conformations with Torsion angles between 30° and 90°, suitably between 45° and 75°, suitably between 50° and 70°, suitably between 53° and 65° at these positions.
  • a tocol compound having these torsion angles is depicted in FIG. 1 . In a straight line drawing the torsion angles are depicted as follows:
  • the compounds have a hydrocarbon tail with a carbon-carbon double bond.
  • the double bond may be between one of carbons 15′, 8′, 9′, 10′, 11′, 12′, 13′, and 14′, suitably the double bond is between carbons 11′ and 12′.
  • the compounds may have a hydrocarbon tail with two or three carbon-carbon double bonds.
  • the carbon-carbon double bonds may be between at least one of carbons 15′, 8′, 9′, 10′, 11′, 12′, 13′, and 14′, suitably carbons 11′ and 12′ and at least one of carbons 1′-2′, 2′-3′,3′-4′, 4′-16′, 8′-15′, 8′-9′ or 9′-10′.
  • the hydrocarbon tails do not have a carbon-carbon double bond between carbons 5′-6′, 6′-7′ or 7′-8′ in the trans configuration.
  • the compounds have a hydrocarbon tail with two carbon-carbon double bonds.
  • the carbon-carbon double bonds are between at least one of carbons 15′, 8′, 9′, 10′, 11′, 12′, 13′, and 14′, suitably carbons 11′ and 12′ and at least one of carbons 1′-2′, 2′-3′,3′-4′, 7′-8′ (in cis) and 4′-16′.
  • the compounds have a hydrocarbon tail with three carbon-carbon double bonds.
  • the carbon-carbon double bonds are between at least one of carbons 15′, 8′, 9′, 10′, 11′, 12′, 13′, and 14′, suitably carbons 11′ and 12′, and 7′-8′ (in cis) and one of carbons 1′-2′, 2′-3′,3′-4′, and 4′-16′.
  • the hydrocarbon tail has a double bond between at least one of carbons 15′, 8′, 9′, 10′, 11′, 12′, 13′, and 14′, suitably carbons 11′ and 12′ and between one of carbons 1′-2′, 2′-3′,3′-4′, and 4′-16′ and contains a cyclopropyl group including carbons 7′ and 8′ and a carbon 17′ not shown in formula II.
  • the hydrocarbon tail with the optional cyclopropyl group may have one of the following configurations with the carbon-double bond shown between carbons 3′ and 4′ as an optional double bond:
  • the hydrocarbon tails described herein may have at least one stereocenter.
  • the compounds of the invention may be present as a racemic mixture of compounds or stereoisomers.
  • certain isomers may be more effective in terms of binding and transport by the ⁇ TTP receptor or may have different or distinct bioactivity, bioavailability or pharmacokinetics.
  • the RS configuration is expected to bind and be transported more efficiently than other isomers. Thus preparation and isolation of the most effective stereoisomers may result in relative pure preparations. If either isomer is in enantiomeric excess of over 50%, the compound is suitably over 80% in the RS structure. Suitably, the compound is over 80%, 85%, 90%, 95%, 98%, 99% a single stereoisomer, such as the RS stereoisomer.
  • R 2 is an —OH.
  • R 2 is an ester. If R 2 is an ester it may be an ester selected from —O(CO)CH 3 , —O(CO)heterocyclic, O(CO)carbocyclic, —O(CO)(R 7 )COOH, —O(CO)R 8 , wherein R 7 is selected from a branched or unbranched, saturated or unsaturated, substituted or unsubstituted C 1 -C 20 alkyl and R 8 is selected from —H, and a branched or unbranched, saturated or unsaturated, substituted or unsubstituted C 1 -C 20 alkyl.
  • R 2 is —NHR 6 , —CO 2 H, —C(R 6 ) 2 CO 2 H or a branched or unbranched, substituted or unsubstituted, saturated or unsaturated C 1 -C 6 alkyl or hydroxyalkyl.
  • R 6 is suitably a —H, —OH or —CH 3 .
  • Y is an —O—.
  • R 5 is suitably either a —H or a —CH 3 .
  • R 1 , R 3 and R 4 are suitably a C 1 -C 6 branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl.
  • R 1 , R 3 , R 4 and R 5 are selected from —H and —CH 3 , R 2 is —OH or an ester, Y is —O—, and the hydrocarbon tail (Z) has at least a double bond between carbons 11′ and 12′.
  • R 5 is —H.
  • R 1 , R 3 and R 4 are all CH 3 .
  • R 3 and R 4 are CH 3 and R 1 is H. In another embodiment, R′ and R 4 are CH 3 and R 3 is H. In another embodiment, R 1 , R 3 and R 4 are H.
  • Each R group is independently selected and may be combined in any manner and with any of the hydrocarbon tails described herein.
  • One exemplary embodiment of the compounds of the invention is as shown below:
  • “Substituted” means that one or more of the hydrogen atoms bonded to carbon atoms in the chain or ring have been replaced with other substituents. Suitable substituents include monovalent hydrocarbon groups including alkyl groups such as methyl groups and monovalent heterogeneous groups including alkoxy groups such as methoxy groups. “Unsubstituted” means that the carbon chain or ring contains no other substituents other than carbon and hydrogen.
  • Branched means that the carbon chain is not simply a linear chain. “Unbranched” means that the carbon chain is a linear carbon chain.
  • “Saturated” means that the carbon chain or ring does not contain any double or triple bonds. “Unsaturated” means that the carbon chain or ring contains at least one double bond. An unsaturated carbon chain or ring may include more than one double bond.
  • Heterogeneous group means a saturated or unsaturated chain of non-hydrogen member atoms comprising carbon atoms and at least one heteroatom.
  • Hydrocarbon group means a chain of 1 to 25 carbon atoms, suitably 1 to 12 carbon atoms, more suitably 1 to 10 carbon atoms, and most suitably 1 to 8 carbon atoms. Hydrocarbon groups may have a linear or branched chain structure. Suitably the hydrocarbon groups have one branch.
  • Carbocyclic group means a saturated or unsaturated hydrocarbon ring. Carbocyclic groups are not aromatic. Carbocyclic groups are monocyclic or polycyclic. Polycyclic carbocyclic groups can be fused, spiro, or bridged ring systems. Monocyclic carbocyclic groups contain 4 to 10 carbon atoms, suitably 4 to 7 carbon atoms, and more suitably 5 to 6 carbon atoms in the ring. Bicyclic carbocyclic groups contain 8 to 12 carbon atoms, preferably 9 to 10 carbon atoms in the rings.
  • Heteroatom means an atom other than carbon e.g., in the ring of a heterocyclic group or the chain of a heterogeneous group.
  • heteroatoms are selected from the group consisting of sulfur, phosphorous, nitrogen and oxygen atoms.
  • Groups containing more than one heteroatom may contain different heteroatoms.
  • Heterocyclic group means a saturated or unsaturated ring structure containing carbon atoms and 1 or more heteroatoms in the ring. Heterocyclic groups are not aromatic. Heterocyclic groups are monocyclic or polycyclic. Polycyclic heteroaromatic groups can be fused, spiro, or bridged ring systems. Monocyclic heterocyclic groups contain 4 to 10 member atoms (i.e., including both carbon atoms and at least 1 heteroatom), suitably 4 to 7, and more suitably 5 to 6 in the ring. Bicyclic heterocyclic groups contain 8 to 18 member atoms, suitably 9 or 10 in the rings.
  • salts of the compounds described herein are also provided.
  • the salts are pharmaceutically acceptable.
  • Acceptable salts of the compounds include, but are not limited to hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate.
  • the compounds described have enhanced binding to the ⁇ -TTP receptor and enhanced transport out of the liver and into the circulation after administration to a subject.
  • the enhanced transport is expected to lead to enhanced biological activity of the compounds as compared to tocotrienol after administration to a subject.
  • the elimination half-life from the subject is also expected to be enhanced.
  • This enhancement of uptake into the blood stream combined with decreased clearance from the body may result in increased effectiveness of administration of the compound or may allow for the therapeutically effective dose of the compounds described herein to be lower than that of tocotrienol or other tocols.
  • the subject may be any mammal, including but not limited to a human, mouse, or domesticated animal.
  • the compounds may have other activities in addition to increased receptor mediated uptake into the blood stream.
  • the hydrocarbon tail may allow farnesyl recognition or confer HMGCoA reductase inhibition activity.
  • the hydrocarbon tail composition may also affect the bioactivity of the compound.
  • compositions comprising the compound of formula (I) or any of the compounds described above and a pharmaceutically acceptable carrier are provided.
  • a pharmaceutically acceptable carrier is any carrier suitable for in vivo administration. Examples of pharmaceutically acceptable carriers suitable for use in the composition include, but are not limited to, water, buffered solutions, glucose solutions, oil-based or bacterial culture fluids. Additional components of the compositions may suitably include, for example, excipients such as stabilizers, preservatives, diluents, emulsifiers and lubricants.
  • Examples of pharmaceutically acceptable carriers or diluents include stabilizers such as carbohydrates (e.g., sorbitol, mannitol, starch, sucrose, glucose, dextran), proteins such as albumin or casein, protein-containing agents such as bovine serum or skimmed milk and buffers (e.g., phosphate buffer). Especially when such stabilizers are added to the compositions, the composition is suitable for freeze-drying or spray-drying. The composition may also be emulsified.
  • carbohydrates e.g., sorbitol, mannitol, starch, sucrose, glucose, dextran
  • proteins such as albumin or casein
  • protein-containing agents such as bovine serum or skimmed milk
  • buffers e.g., phosphate buffer
  • the compounds described herein may be used to treat a subject with a condition selected from radiation exposure, cancer, cardiovascular disease including but not limited to coronary artery disease, decreasing lipoprotein levels, decreasing cholesterol levels, decrease triglyceride levels and the like, age-related macular degeneration, cataracts, glaucoma, chronic pain, chronic fatigue syndrome, fever, edema, diabetes mellitus, signs of aging, rheumatoid diseases, septic shock, or Alzheimer's disease.
  • the compounds may be delivered as a radioprotective agent to a subject prior to potential exposure to radiation, such as to a patient receiving radiation therapy, or a person working with or cleaning up radiation.
  • the compounds may also be given after radiation exposure as a radiomitigator, such as after an accident involving the release of radiation.
  • Treatment of a condition includes but is not limited to, prophylaxis of symptoms or indicators of the condition, reduction in disease severity, or reversal, reduction or slowing in disease progression as compared to an untreated subject.
  • the compounds described herein may be used to treat subjects in need of treatment with an antioxidant, an anti-inflammatory, immunoregulatory, antithromobotic, antiatherogenic, hypocholesterolemic or an HMG-CoA reductase inhibitor.
  • the compounds may be useful to increase the feed conversion efficiency of domesticated animals including livestock.
  • Combination therapy with a known antioxidant, anti-inflammatory or HMG-CoA reductase inhibitor may result in increased effectiveness of the combination treatment as compared to treatment with either compound alone.
  • the compounds described herein may be administered by any means known to those skilled in the art, including, but not limited to, oral, topical, intranasal, intraperitoneal, parenteral, intravenous, intramuscular, or subcutaneous.
  • the compounds may be formulated as an ingestable, injectable, topical or suppository formulation.
  • the compounds may also be delivered with in a liposomal or time-release vehicle.
  • Administration of the compounds to a subject in accordance with the invention appears to exhibit beneficial effects in a dose-dependent manner. Thus, within broad limits, administration of larger quantities of the compounds is expected to achieve increased beneficial biological effects than administration of a smaller amount. Moreover, efficacy is also contemplated at dosages below the level at which toxicity is seen.
  • the specific dosage administered in any given case will be adjusted in accordance with the compound or compounds being administered, the disease to be treated or inhibited, the condition of the subject, and other relevant medical factors that may modify the activity of the compound or the response of the subject, as is well known by those skilled in the art.
  • the specific dose for a particular subject depends on age, body weight, general state of health, diet, the timing and mode of administration, the rate of excretion, medicaments used in combination and the severity of the particular disorder to which the therapy is applied.
  • Dosages for a given patient can be determined using conventional considerations, e.g., by customary comparison of the differential activities of the compound of the invention and of a known agent such as tocopherol, such as by means of an appropriate conventional pharmacological or prophylactic protocol.
  • the maximal dosage for a subject is the highest dosage that does not cause undesirable or intolerable side effects.
  • the number of variables in regard to an individual prophylactic or treatment regimen is large, and a considerable range of doses is expected.
  • the route of administration will also impact the dosage requirements. It is anticipated that dosages of the compound will reduce symptoms of the condition at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% compared to pre-treatment symptoms or symptoms is left untreated. It is specifically contemplated that pharmaceutical preparations and compositions may palliate or alleviate symptoms of the disease without providing a cure, or, in some embodiments, may be used to cure the disease or disorder.
  • Suitable effective dosage amounts for administering the compounds may be determined by those of skill in the art, but typically range from about 1 microgram to about 100,000 micrograms per kilogram of body weight weekly, although they are typically about 1,000 micrograms or less per kilogram of body weight weekly. Like other vitamin E compounds, large doses may be required for therapeutic effect and toxicity of the compounds is likely low. In some embodiments, the effective dosage amount ranges from about 10 to about 10,000 micrograms per kilogram of body weight weekly. In another embodiment, the effective dosage amount ranges from about 50 to about 5,000 micrograms per kilogram of body weight weekly. In another embodiment, the effective dosage amount ranges from about 75 to about 1,000 micrograms per kilogram of body weight weekly.
  • the effective dosage amounts described herein refer to total amounts administered, that is, if more than one compound is administered, the effective dosage amounts correspond to the total amount administered.
  • the compound can be administered as a single dose or as divided doses.
  • the composition may be administered two or more times separated by 4 hours, 6 hours, 8 hours, 12 hours, a day, two days, three days, four days, one week, two weeks, or by three or more weeks.
  • FIG. 1 demonstrates that the hydrocarbon tail must fold at two torsion points. Torsion angle A is suitably about 61° and Torsion B is suitably at about 58.4°. Thus tocols with a flexible tail capable of conforming to these angles are contemplated. The central location of the torsion is shown in the drawing below.
  • the heat map of the interaction between various tocols and the ⁇ TTP receptor is shown in FIG. 2 .
  • the circled area on the heat map shows the key interaction distinction between RRR- ⁇ -tocopherol and R- ⁇ -tocotrienol.
  • the heat map for RS- ⁇ -tocoflexol is quite similar to that of tocopherol and thus binding to ⁇ TTP receptor is expected to be similar to that of tocopherol.
  • the heat map for RR- ⁇ -tocoflexol lacks this key predicted interaction and thus is expected to bind ⁇ TTP less efficiently.
  • Compound 1 is synthesized by a reaction between a chiral chromanyl group and C15 alkyl chain built as shown below.
  • FIG. 3 An alternative synthesis scheme to make the compounds of formula I is depicted in FIG. 3 .
  • GC/MS Gas chromatography-mass spectrometry
  • the ability of the compounds described herein to bind ⁇ -TTP will be measured as described in Panagabko et al, 2003 Biochemistry 42:6467-74.
  • the Vitamin E activity of the compounds will be assessed by the method of Leth et al, 1977 J. Nutr. 107:2236-43. Specific activity, for example, as radioprotectors, will be assessed in vitro and in vivo using standard assays.
  • the compounds will be used in the following assays: in vitro radiation toxicity assays (clonogenic cell survival, cytogenetics, and measurement of oxidative stress) and in vivo studies (hematopoietic, gastrointestinal, pulmonary, cutaneous, and neurovascular subsyndromes of the acute radiation syndrome).
  • in vitro radiation toxicity assays clonogenic cell survival, cytogenetics, and measurement of oxidative stress
  • in vivo studies hematopoietic, gastrointestinal, pulmonary, cutaneous, and neurovascular subsyndromes of
  • the compounds described herein and ⁇ -tocopherol and ⁇ -tocotrienol will be combined with food or provided in tablet form to subjects over a period of four weeks. At various times post-administration blood samples will be harvested from the subjects and the amount of the compound present in the blood will be compared. Subjects will be tested for blood lipoprotein levels prior to receiving the compounds and after 4 weeks of treatment. After 4 weeks of treatment we expect the compounds of the invention will cause a significant reduction in the levels of lipoproteins in the blood of treated individuals as compared to untreated controls and as compared to those treated with ⁇ -tocopherol or ⁇ -tocotrienol.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US13/701,630 2010-06-02 2011-06-02 Tocopherol derivatives and methods of use Abandoned US20130158106A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/701,630 US20130158106A1 (en) 2010-06-02 2011-06-02 Tocopherol derivatives and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35074010P 2010-06-02 2010-06-02
PCT/US2011/038933 WO2011153353A1 (fr) 2010-06-02 2011-06-02 Dérivés de tocophérol et leurs méthodes d'utilisation
US13/701,630 US20130158106A1 (en) 2010-06-02 2011-06-02 Tocopherol derivatives and methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/038933 A-371-Of-International WO2011153353A1 (fr) 2010-06-02 2011-06-02 Dérivés de tocophérol et leurs méthodes d'utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/969,601 Continuation US20180244641A1 (en) 2010-06-02 2018-05-02 Tocopherol derivatives and methods of use

Publications (1)

Publication Number Publication Date
US20130158106A1 true US20130158106A1 (en) 2013-06-20

Family

ID=45067073

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/701,630 Abandoned US20130158106A1 (en) 2010-06-02 2011-06-02 Tocopherol derivatives and methods of use
US15/969,601 Abandoned US20180244641A1 (en) 2010-06-02 2018-05-02 Tocopherol derivatives and methods of use
US17/857,879 Pending US20220332692A1 (en) 2010-06-02 2022-07-05 Tocopherol derivatives and methods of use

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/969,601 Abandoned US20180244641A1 (en) 2010-06-02 2018-05-02 Tocopherol derivatives and methods of use
US17/857,879 Pending US20220332692A1 (en) 2010-06-02 2022-07-05 Tocopherol derivatives and methods of use

Country Status (2)

Country Link
US (3) US20130158106A1 (fr)
WO (1) WO2011153353A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016190852A1 (fr) * 2015-05-26 2016-12-01 Stealth Peptides International, Inc. Compositions thérapeutiques comprenant des composés chromanyle, des variants et des analogues associés, et leurs utilisations
US11116746B2 (en) 2015-05-05 2021-09-14 Tocol Pharmaceuticals, Llc Use of rice bran oil distillate extract for prevention and mitigation of the effects of radiation

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2874583C (fr) * 2012-05-22 2018-10-02 The Board Of Trustees Of The University Of Arkansas Procedes de fabrication de tocoflexols et de leurs analogues
CA2924126C (fr) 2013-09-13 2023-05-02 The Board Of Trustees Of The University Of Arkansas Preparation et utilisation d'une composition pour la prevention et l'attenuation des effets de rayonnements
BR112020019757A2 (pt) 2018-03-29 2021-03-02 Dsm Ip Assets B.V. uso inovador de croman-6-óis substituídos com cadeias laterais lipofílicas estendidas
CN112898162A (zh) * 2021-01-22 2021-06-04 江西农业大学 一种氢化柠檬基叔胺的合成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350453B1 (en) * 1999-05-24 2002-02-26 American River Nutrition, Inc. Tocotrienols and geranylgeraniol from Bixa orellana byproducts
US20090041870A1 (en) * 2003-04-10 2009-02-12 Barrie Tan Annatto Extract Compositions Including Tocotrienols and Tocopherols and Methods of Use
US20100036079A1 (en) * 2007-03-12 2010-02-11 Emilia Tiitinen Use of tocopherol
US20150087033A1 (en) * 2012-05-22 2015-03-26 The Board Of Trustees Of The University Of Arkansas Methods for making tocoflexols and analogues thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037102A1 (en) * 2003-07-18 2005-02-17 Barrie Tan Annatto extract compositions including tocotrienols and tocopherols and methods of use
EP2279251A2 (fr) * 2008-04-23 2011-02-02 Danisco US Inc. Variants d isoprène synthases améliorant la production microbienne d isoprène

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350453B1 (en) * 1999-05-24 2002-02-26 American River Nutrition, Inc. Tocotrienols and geranylgeraniol from Bixa orellana byproducts
US20090041870A1 (en) * 2003-04-10 2009-02-12 Barrie Tan Annatto Extract Compositions Including Tocotrienols and Tocopherols and Methods of Use
US20100036079A1 (en) * 2007-03-12 2010-02-11 Emilia Tiitinen Use of tocopherol
US8044161B2 (en) * 2007-03-12 2011-10-25 Bayer Shering Pharma Oy Use of tocopherol
US20150087033A1 (en) * 2012-05-22 2015-03-26 The Board Of Trustees Of The University Of Arkansas Methods for making tocoflexols and analogues thereof
US9309547B2 (en) * 2012-05-22 2016-04-12 The Board Of Trustees Of The University Of Arkansas Methods for making tocoflexols and analogues thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Axel Wolfgang Buss (Diastereoselective synthesis of alpha-tocopherol, Inauguraldissertation, Basel November 11, 2008) *
Odinokov et al. (ARKIVOC, 2003 (xiii) 101-118) *
Puah et al. (Accession number 2007:570983, CAPLUS, DN 147:425926, The effect of physical refining on palm vitamin E (tocopherol, tocotrienol and tocomonoenol, American Journal of Applied Sciences (2007), 4(6) 374-377). *
Rammell et al. (AN 1985:467656, CAPLUS, DN 103:67656, ORIGINAL REFERENCE NO.: 103:10829a, 10832a, Separation of tocols by HPLC on an amino-cyano polar phase column, Journal of Liquid Chromatography (1985), 8(4), 707-17). *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116746B2 (en) 2015-05-05 2021-09-14 Tocol Pharmaceuticals, Llc Use of rice bran oil distillate extract for prevention and mitigation of the effects of radiation
WO2016190852A1 (fr) * 2015-05-26 2016-12-01 Stealth Peptides International, Inc. Compositions thérapeutiques comprenant des composés chromanyle, des variants et des analogues associés, et leurs utilisations

Also Published As

Publication number Publication date
US20220332692A1 (en) 2022-10-20
US20180244641A1 (en) 2018-08-30
WO2011153353A1 (fr) 2011-12-08

Similar Documents

Publication Publication Date Title
US20220332692A1 (en) Tocopherol derivatives and methods of use
EP3634430B1 (fr) Agents multibiotiques et procédés d'utilisation de ceux-ci
US6054486A (en) Use of 9-Deoxy-2',9-α-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen e)-13,14-dihydro-prostaglandin f1 to treat peripheral vascular disease
US20040014806A1 (en) Methods and compositions for lowering levels of blood lipids
CA2513427C (fr) Composes possedant des proprietes antiproliferatives
US20150119359A1 (en) Sulforaphane isolation and purification
US9713597B2 (en) Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone
JP2019038819A (ja) 放射線の影響から防護するため及び放射線の影響を緩和するための組成物の調製及び使用
JP2024175025A (ja) 組織の灌流の増加における使用のためのイノシトールリン酸化合物
US8614228B2 (en) Quinone prodrug compositions and methods of use
US20050227930A1 (en) Cholesterol lowering combination
EP2120925A1 (fr) Procédé d'induction d'autophagie
KR20100136494A (ko) 아포에쿼린 함유 조성물 및 이의 사용 방법
US20110038827A1 (en) Elevation of the plasma hdl-cholesterol level
EP0427518B1 (fr) Composés de NMDA-blocage, compositions pharmaceutiques, leur préparation et leur usage
EP3007721B1 (fr) Bioconjugués de composés mimétique d'amyline et de polyéthylèneglycol ne s'agglomérant pas
CN110087646A (zh) 单体双金属羟基柠檬酸化合物及其制备和使用方法
CA2531810A1 (fr) Compositions et procede pour traiter la maladie de parkinson et la diskynesie tardive
US10052305B2 (en) Lipoic acid and derivatives thereof for the treatment of cystinuria
US20250249108A1 (en) Prodrugs for cancer treatment
CN103260614B (zh) 联合疗法
JP2023141229A (ja) 高リン血症治療用医薬用組成物
AU2004200762B2 (en) Compounds having anti-proliferative properties
US20210107855A1 (en) Hydroxycitric acid metal heterocyclic compounds with covalent characteristics

Legal Events

Date Code Title Description
AS Assignment

Owner name: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COMPADRE, CESAR;BREEN, PHILIP J.;HAUER-JENSEN, MARTIN;AND OTHERS;SIGNING DATES FROM 20120611 TO 20120808;REEL/FRAME:030626/0625

Owner name: UNITED STATES OF AMERICA, AS REPRESENTED BY THE DE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HAUER-JENSEN, MARTIN;REEL/FRAME:030626/0728

Effective date: 20120612

AS Assignment

Owner name: BIOVENTURES, LLC, ARKANSAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS;REEL/FRAME:042336/0049

Effective date: 20170309

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION